Philrivers announced that it has raised $15 million in a round of funding led by investors, Insight Venture Management, LLC and Taiya Capital on July 7, 2022. The transaction also included participation from investors, Beijing Highthink Pharmaceutical Technology Service Co., Ltd., Novogene Co., Ltd. (SHSE:688315).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.3 CNY | +1.29% | +1.68% | -43.02% |
Apr. 12 | Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 27 | Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.02% | 758M | |
-24.16% | 7.76B | |
+68.65% | 4.33B | |
+2.72% | 2.63B | |
-2.98% | 2.64B | |
-46.17% | 2.16B | |
-15.27% | 1.75B | |
-22.12% | 1.46B | |
+13.62% | 1.17B | |
-43.81% | 1.14B |
- Stock Market
- Equities
- 688315 Stock
- News Novogene Co., Ltd.
- Philrivers announced that it has received $15 million in funding from Insight Venture Management, LLC, Beijing Highthink Pharmaceutical Technology Service Co., Ltd., Novogene Co., Ltd. and other investor